Persistent viruses, such as herpes simplex (HSV), hepatitis B (HBV), and Human immunodeficiency virus (HIV) remain serious causes of human suffering and death. After initial infection, these viruses establish latency or stable persistence in long-lived cells. Current antivirals can suppress viral replication, but they do not eliminate the persistent viral forms, which serve as the source for viral reactivation once treatment is stopped. To address the need for novel therapeutic approaches to cure these infections, we have evaluated the use of gene-editing endonucleases to directly target persistent virus in vivo. Our experience supports continued efforts toward gene editing as an antiviral strategy, emphasizes the importance of efficient delivery for in vivo gene editing applications, and should encourage workers in the field to appreciate the full diversity of available gene-editing nucleases.
After viewing this lecture, participants should be able to:
1. Identify the principles of gene editing and why gene editing may be appropriate for persistent viruses
2. Contrast the unique characteristics of different target viruses, such as HIV, hepatitis B, and herpes simplex
3. Consider future challenges to effective application of gene editing for viruses
Keith Jerome, MD, PhD
Professor, Head of Virology Division
Director, Molecular Virology Laboratory
Dept of Laboratory Medicine, University of Washington
uw.edu/video
10/30/19